The stock of Affimed NV (NASDAQ:AFMD) registered a decrease of 6.84% in short interest. AFMD’s total short interest was 759,500 shares in September as published by FINRA. Its down 6.84% from 815,300 shares, reported previously. With 63,800 shares average volume, it will take short sellers 12 days to cover their AFMD’s short positions. The short interest to Affimed NV’s float is 6.84%. About 48,397 shares traded hands. Affimed NV (NASDAQ:AFMD) has declined 3.01% since February 8, 2016 and is downtrending. It has underperformed by 19.50% the S&P500.
Affimed N.V. is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The company has a market cap of $95.07 million. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. It currently has negative earnings. The Company’s pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs.
Out of 5 analysts covering Affirmed N.V. (NASDAQ:AFMD), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $17 is the highest target while $4 is the lowest. The $8.50 average target is 209.09% above today’s ($2.75) stock price. Affirmed N.V. has been the topic of 9 analyst reports since October 15, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock on May 19 with “Hold” rating. BMO Capital Markets initiated the shares of AFMD in a report on April 12 with “Outperform” rating. Lastly, Wells Fargo initiated the stock with “Outperform” rating in a December 4 report.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.